A Phase II Study of Locally Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The primary end point is to evaluate the 9-month progression free survival rate and safety
profile after FOLFIRINOX versus GOFL induction chemotherapy followed by concurrent
chemoradiotherapy in locally advanced pancreatic cancer.
The secondary end points are to evaluate the disease control rate, overall survival time,
toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy
as well as the disease control rate after inductional chemotherapy alone in locally advanced
pancreatic cancer. Translational research including pharmacogenomic study and biomarker study
will also be done concomitantly.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
National Cheng-Kung University Hospital National Taiwan University Hospital